Literature DB >> 8943173

Familial hyperparathyroidism without multiple endocrine neoplasia.

S M Huang1, Q Y Duh, J Shaver, A E Siperstein, J L Kraimps, O H Clark.   

Abstract

Hyperparathyroidism occurs sporadically, in association with multiple endocrine neoplasia (MEN) types I and II, or rarely as familial hyperparathyroidism (FHPT) without other manifestations. We analyzed our experience in 16 FHPT patients from 14 families treated between 1934 and 1991 and reviewed 51 other FHPT patients reported in the literature to determine the clinical course of these patients. Among our 16 patients, 7 (44%) had a serum calcium level >/= 3.75 mmol/L, 5 (31%) presented with hypercalcemic crisis, 3 (19%) had osteitis fibrosa cystica, 5 (31%) had nephrolithiasis, 1 had pancreatitis, 12 (75%) had multiple abnormal parathyroid glands, 3 (19%) had supernumerary glands, and 7 (44%) required reoperation for persistent (n = 4) or recurrent (n = 3) hyperparathyroidism. Three patients (19%) also had papillary thyroid cancer, and 7 (44%) had other coexistent thyroid disorders. Among 51 patients with FHPT reported in the literature, 23 (45%) had serum calcium >/= 3.75 mmol/L, and 23 (45%) had multiple abnormal parathyroid glands; 10 (20%) had recurrent hyperparathyroidism. FHPT without other endocrinopathies is a distinct entity. Patients with FHPT have multiple abnormal parathyroid glands and are prone to both recurrent and persistent hyperparathyroidism. They frequently present with profound hypercalcemia or hypercalcemic crisis, in contrast to patients with MEN-associated hyperparathyroidism or sporadic hyperparathyroidism.

Entities:  

Mesh:

Year:  1997        PMID: 8943173     DOI: 10.1007/s002689900188

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  10 in total

Review 1.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

2.  Familial hyperparathyroidism: report of a case.

Authors:  H Abe; T Tani; H Naito; E Mekata; H Sako; J Ioka; M Kodama
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 3.  Genetic basis of familial isolated hyperparathyroidism: a case series and a narrative review of the literature.

Authors:  Nikolaos Pontikides; Spyridon Karras; Athina Kaprara; Panagiotis Anagnostis; Gesthimani Mintziori; Dimitrios G Goulis; Eleni Memi; Gerasimos Krassas
Journal:  J Bone Miner Metab       Date:  2014-01-19       Impact factor: 2.626

4.  New Concepts About Familial Isolated Hyperparathyroidism.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2019-03-08       Impact factor: 5.958

5.  Hyperparathyroidism-jaw tumor syndrome: Results of operative management.

Authors:  Amit Mehta; Dhaval Patel; Avi Rosenberg; Myriem Boufraqech; Ryan J Ellis; Naris Nilubol; Martha M Quezado; Stephen J Marx; William F Simonds; Electron Kebebew
Journal:  Surgery       Date:  2014-10-16       Impact factor: 3.982

Review 6.  Bilateral neck exploration in primary hyperparathyroidism--when is it selected and how is it performed?

Authors:  Jacob Moalem; Marlon Guerrero; Electron Kebebew
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

7.  A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.

Authors:  Virginia Bellido; Ihintza Larrañaga; Maite Guimón; Rafael Martinez-Conde; Asier Eguia; Gustavo Perez de Nanclares; Luis Castaño; Sonia Gaztambide
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

8.  Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.

Authors:  Maurizio Iacobone; Giulia Masi; Luisa Barzon; Andrea Porzionato; Veronica Macchi; Francesco Antonio Ciarleglio; Giorgio Palù; Raffaele De Caro; Giovanni Viel; Gennaro Favia
Journal:  Langenbecks Arch Surg       Date:  2009-06-16       Impact factor: 3.445

Review 9.  Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.

Authors:  C Christofer Juhlin; Lori A Erickson
Journal:  Endocr Pathol       Date:  2020-12-02       Impact factor: 3.943

10.  CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma.

Authors:  Eeva Korpi-Hyövälti; Treena Cranston; Eeva Ryhänen; Johanna Arola; Kristiina Aittomäki; Timo Sane; Rajesh V Thakker; Camilla Schalin-Jäntti
Journal:  J Clin Endocrinol Metab       Date:  2014-05-13       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.